YouTube video by Transcending Obscurity

YouTube video by Spazm

us stock pros (@usstockpros) / X

YouTube video by sasakure. UK

YouTube video by sasakure. UK

YouTube video by 反動のゲームちゃんねる(Hando's Game Channel)

The proposed proprietary name, or brand name, CIFBEZY has received conditional acceptance from the FDA and also federal trademark allowance from the USPTO These initial milestones will form the basis for the commercial identity of Acurx's lead product candidate, ibezapolstat, as the Company prepares to advance it toward its international Phase 3...

Acurx reported $10.7 million in cash, a $2.3 million Q2 loss and higher R&D spending as ibezapolstat development advanced.

Acurx Pharmaceuticals (NASDAQ: ACXP) reported second quarter 2026 results and a business update for the period ended June 30, 2026. Cash totaled $10.7 million, up from $7.6 million at December 31, 2025, supported by a $2.5 million registered direct offering, $0.8 million raised under an equity line, and new short‑term warrants for 1,650,170 shares.Q2 research and development expenses were $1.1 million versus $0.5 million a year earlier, while general and administrative expenses fell to $1.2 million from $1.7 million. Net loss was $2.3 million ($0.53/share), versus $2.2 million ($1.89/share) in Q2 2025. Operationally, the company advanced ibezapolstat toward Phase 3 in C. difficile infection, received FDA conditional proprietary name acceptance, extended its DNA pol IIIC research partnership with Leiden University Medical Center, presented new microbiome and biofilm data, and obtained additional patents in Japan and Mexico, bringing its portfolio to six U.S. and ten international patents.

STATEN ISLAND, N.Y., Aug. 14, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today certain financial and...

Acurx Pharmaceuticals (NASDAQ: ACXP) announced that the Japan Patent Office and the Mexico Patent Office have each granted new patents covering its DNA Polymerase IIIC inhibitor antibiotics. The patents include compositions of matter, methods of use, and pharmaceutical compositions, expanding protection for ibezapolstat and the ACX‑375C program.According to Acurx, this brings its total to six U.S. patents and ten international patents across Australia, Canada, Europe, Israel, India, Japan, Korea, and Mexico, all focused on DNA Polymerase IIIC–targeting programs. The company notes that additional country-level patent applications remain under review, and management highlights these patents as strengthening its intellectual property estate supporting ibezapolstat and its AI-supported drug discovery platform for difficult-to-treat bacterial infections.

STATEN ISLAND, N.Y., Aug. 12, 2026 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult‑to‑treat bacterial infections, today announced that the Japan...

This new partnership builds on the previously reported successful results from the innovative research grant received in November 2025 from Health-Holland to Leiden University and Acurx This prior work included high-resolution elucidation of the interaction of ibezapolstat with its molecular target, DNA polymerase IIIC, with mechanistic findings...

Acurx Pharmaceuticals (NASDAQ: ACXP) reported new microbiome and in vitro data on its antibiotic ibezapolstat in multiply‑recurrent Clostridioides difficile infection (rCDI), presented at the 18th Biennial Congress of the Anaerobe Society of the Americas.According to Acurx and University of Houston researchers, beneficial gut bacteria involved in bile acid metabolism persist in patients with ≥2 CDI recurrences despite multiple prior vancomycin and/or fidaxomicin courses, and may regrow after ibezapolstat, which showed microbiome selectivity in earlier trials. Laboratory studies indicated ibezapolstat effectively killed C. difficile in planktonic and biofilm co‑culture with Enterococcus, outperforming fidaxomicin in biofilm killing and avoiding vancomycin‑associated VRE overgrowth. Acurx has initiated start‑up activities for a 20‑patient open‑label rCDI pilot trial and plans an active‑controlled Phase 3 rCDI registration trial, alongside an international Phase 3 program in acute CDI, supported by consistent FDA and EMA feedback and existing FDA QIDP/Fast Track and EMA SME designations.

YouTube video by ずんだの本質【人間の不思議系ゆっくり解説】

Wall Street Zen upgraded shares of Acurx Pharmaceuticals (NASDAQ:ACXP – Free Report) to a sell rating in a report published on Saturday. Separately, HC Wainwright reissued a “buy” rating and set a $160.00 target price on shares of Acurx Pharmaceuticals in a research report on Thursday, May 15th. Get Our Latest Analysis on ACXP Acurx […]